Global Antibiotic R&D Partnership (GARDP)
Karin Hergarden has extensive experience in clinical research management, with a focus on overseeing and monitoring various clinical trials in multiple companies. Currently serving as a Clinical Research Manager at Global Antibiotic R&D Partnership (GARDP), Karin has also held positions such as PM/Sr. CRA at Mologen AG (MGN) and CRA at Epicentre. With a background in nursing and a Master's degree in public health, Karin's expertise lies in ensuring the successful implementation and monitoring of clinical studies, along with handling various study-related activities and procedures.
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org